Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018

November 14, 2018 4:55 PM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Baker Bros. Advisors released its 13F for the quarter ended Sept. 30, 2018. Below is a summary:

New Stakes
Aquestive Therapeutics Inc. (NASDAQ: AQST) new 99,600 share position
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) new 307,496 share position
Constellation Pharmaceuticals (NASDAQ: CNST) new 133,333 share position
Crinetics (NASDAQ: CRNX) new 131,250 share position
Principia Biopharma Inc. (NASDAQ: PRNB) new 1,787,807 share position
Viking Systems, Inc. (OTC: VKNG) new 425,000 share position
Y-mAbs Therapeutics (NASDAQ: YMAB) new 150,000 share position

Raised Stakes
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) raised from 27,228,338 shares to 28,439,114 shares
Amarin Corp Plc (NASDAQ: AMRN) raised from 22,669,509 shares to 34,069,509 shares *
argenx (NASDAQ: ARGX) raised from 961,754 shares to 1,019,557 shares
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) raised from 14,012,172 shares to 15,103,081 shares
ACMAT Corporation Class A (NASDAQ: CMTA) raised from 1,192,595 shares to 1,933,624 shares
ENDOCYTE (NASDAQ: ECYT) raised from 2,277,799 shares to 2,548,069 shares
Genomic Health, Inc. (NASDAQ: GHDX) raised from 13,790,574 shares to 13,790,970 shares
GW PHARM SP ADS (NASDAQ: GWPH) raised from 321,800 shares to 396,700 shares
Incyte Genomics, Inc. (NASDAQ: INCY) raised from 34,251,034 shares to 34,251,309 shares
INSMED (NASDAQ: INSM) raised from 700,000 shares to 1,851,982 shares
Molecular Templates (NASDAQ: MTEM) raised from 72,412 shares to 254,230 shares
Spring Bank Pharmaceuticals (NASDAQ: SBPH) raised from 373,144 shares to 613,144 shares

Lowered Stakes
ACCELERON PHARMA (NASDAQ: XLRN) lowered from 163,900 shares to 83,900 shares
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) lowered from 1,943,620 shares to 1,639,948 shares
Aevi Genomic Medicine (NASDAQ: GNMX) lowered from 4,055,142 shares to 3,950,419 shares
Affimed (NASDAQ: AFMD) lowered from 400,000 shares to 200,000 shares
Bellicum Pharma (NASDAQ: BLCM) lowered from 4,093,447 shares to 2,677,818 shares
BLUEBIRD BIO (NASDAQ: BLUE) lowered from 200,000 shares to 59,441 shares
Catyalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) lowered from 3,621,962 shares to 2,900,000 shares
ERYTECH (NASDAQ: ERYP) lowered from 3,085,969 shares to 1,085,969 shares
Foamix (NASDAQ: FOMX) lowered from 1,490,201 shares to 688,075 shares
G1 Therapeutics (NASDAQ: GTHX) lowered from 169,492 shares to 127,236 shares
Galapagos NV (NASDAQ: GLPG) lowered from 259,894 shares to 237,191 shares
Galmed Pharma (NASDAQ: GLMD) lowered from 636,140 shares to 324,094 shares
Halozyme Therapeutics, Inc. (NASDAQ: HALO) lowered from 1,283,929 shares to 449,969 shares
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) lowered from 38,654,811 shares to 4,833,897 shares
InflaRx N.V. (NASDAQ: IFRX) lowered from 258,824 shares to 178,987 shares
Intellia Therapeutics (NASDAQ: NTLA) lowered from 546,922 shares to 192,538 shares
Krystal Biotech (NASDAQ: KRYS) lowered from 200,000 shares to 114,674 shares
MyoKardia (NASDAQ: MYOK) lowered from 433,121 shares to 357,215 shares
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) lowered from 10,000,000 shares to 944,624 shares
Novavax, Inc. (NASDAQ: NVAX) lowered from 73,500,000 shares to 4,718,318 shares
Ovid Therapeutics (NASDAQ: OVID) lowered from 247,733 shares to 222,139 shares
Sagebrush Gold Ltd. (NASDAQ: SAGE) lowered from 613,300 shares to 567,497 shares
Trillium Therapeutics (NASDAQ: TRIL) lowered from 511,763 shares to 505,262 shares
XENCOR (NASDAQ: XNCR) lowered from 872,072 shares to 602,495 shares

Liquidated Stakes
Acorda Therapeutics, Inc. (NASDAQ: ACOR) liquidated
Adaptimmune Therapeutics (NASDAQ: ADAP) liquidated
AERIE PHARMACEUT (NASDAQ: AERI) liquidated
Akari Therapeutcis (NASDAQ: AKTX) liquidated
Arbutus Biopharma (NASDAQ: ABUS) liquidated
BioDelivery Sciences Internati (NASDAQ: BDSI) liquidated
BIOTIME, Inc. (NYSE: BTX) liquidated
Cellectis (NASDAQ: CLLS) liquidated
Corbus Pharma (NASDAQ: CRBP) liquidated
Cyclacel Pharmaceuticals, Inc. (NASDAQ: YCC) liquidated
Exelixis, Inc. (NASDAQ: EXEL) liquidated
GlycoMimetics (NASDAQ: GLYC) liquidated
Jounce Therapeutics (NASDAQ: JNCE) liquidated
MACROGENICS (NASDAQ: MGNX) liquidated
MediWound (NASDAQ: MDWD) liquidated
Nabriva (NASDAQ: NBRV) liquidated
Natera (NASDAQ: NTRA) liquidated
NEWLINK GENETICS (NASDAQ: NLNK) liquidated
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) liquidated
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) liquidated
Selecta Biosciences (NASDAQ: SELB) liquidated
Sesen Bio (NASDAQ: SESN) liquidated
STEMLINE THRPTS (NASDAQ: STML) liquidated
T2 Biosystems (NASDAQ: TTOO) liquidated
TETRAPH PHARMA (NASDAQ: TTPH) liquidated
Tonix Pharma (NASDAQ: TNXP) liquidated
TREVENA (NASDAQ: TRVN) liquidated
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) liquidated

Maintained Stakes
Abeona Therapeutics (NASDAQ: ABEO) maintained 2,184,364 share stake
ADAMAS PHARMACEUT (NASDAQ: ADMS) maintained 172,630 share stake
Aeglea BioTherapeutics (NASDAQ: AGLE) maintained 1,387,872 share stake
AIMSI Technologies (NASDAQ: AIMT) maintained 673,908 share stake
Albireo Pharma (NASDAQ: ALBO) maintained 250,000 share stake
Alexion Pharmaceuticals (NASDAQ: ALXN) maintained 8,555,894 share stake
ALKERMES (NASDAQ: ALKS) maintained 100,251 share stake
Apellis Pharmaceuticals (NASDAQ: APLS) maintained 196,078 share stake
Aquinox Pharma (NASDAQ: AQXP) maintained 10,934,154 share stake
Arcus Biosciences (NYSE: RCUS) maintained 121,534 share stake
Array Biopharma, Inc. (NASDAQ: ARRY) maintained 5,656,196 share stake
Ascendis Pharma (NASDAQ: ASND) maintained 2,837,352 share stake
Assembly Biosciences (NASDAQ: ASMB) maintained 148,587 share stake
Bold Energy, Inc. (NASDAQ: BOLD) maintained 393,222 share stake
Autolus Therapeutics (NASDAQ: AUTL) maintained 235,294 share stake
BeiGene (NASDAQ: BGNE) maintained 11,959,824 share stake
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) maintained 7,583,084 share stake
Cerus Corp (NASDAQ: CERS) maintained 10,749,937 share stake
CHEMOCENTRYX (NASDAQ: CCXI) maintained 414,029 share stake
ContraFect (NASDAQ: CFRX) maintained 7,153,076 share stake
(: ) maintained 10,000,000 share stake
CAL-BAY INTL (NASDAQ: CBAY) maintained 4,917,700 share stake
DBV Technologies (NASDAQ: DBVT) maintained 5,509,560 share stake
Dynavax Technologies Corporation (NASDAQ: DVAX) maintained 75,000 share stake
Forty Seven Inc. (NASDAQ: FTSV) maintained 250,000 share stake
Fulgent Genetics, Inc. (NASDAQ: FLGT) maintained 125,000 share stake
HERON THERAPEUTICS (NASDAQ: HRTX) maintained 5,025,298 share stake
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) maintained 580,400 share stake
InVitae (NYSE: NVTA) maintained 8,399,411 share stake
Kiniksa (NASDAQ: KNSA) maintained 3,000,000 share stake
LA JOLLA PHARMACEUT (NASDAQ: LJPC) maintained 154,675 share stake
Madrigal Pharma (NASDAQ: MDGL) maintained 1,169,278 share stake
Menlo Therapeutics (NASDAQ: MNLO) maintained 700,000 share stake
Merus N.V. (NASDAQ: MRUS) maintained 1,160,014 share stake
MIRATI THER (NASDAQ: MRTX) maintained 2,513,462 share stake
Monarch Casino & Resort, Inc. (NASDAQ: MCRI) maintained 308,500 share stake
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) maintained 10,000,000 share stake
Proteon Therapeutics (NASDAQ: PRTO) maintained 298,591 share stake
Ra Pharmaceuticals (NASDAQ: RARX) maintained 177,952 share stake
Rhythm Pharmaceuticals (NASDAQ: RYTM) maintained 2,708,200 share stake
Ritter Pharma (NASDAQ: RTTR) maintained 279,999 share stake
Sangamo Biosciences, Inc. (NASDAQ: SGMO) maintained 1,283,923 share stake
Seattle Genetics Inc /wa (NASDAQ: SGEN) maintained 51,046,060 share stake
Solid Biosciences (NASDAQ: SLDB) maintained 587,884 share stake
One E-Commerce Corp (NASDAQ: ONCE) maintained 1,384,130 share stake
Sunesis Pharmaceuticals (NASDAQ: SNSS) maintained 556,665 share stake
Syros Pharmaceuticals (NASDAQ: SYRS) maintained 574,835 share stake
Tricida (NASDAQ: TCDA) maintained 1,600,000 share stake
UNIQURE (NASDAQ: QURE) maintained 605,000 share stake
VERSARTIS (NASDAQ: VSAR) maintained 2,426,310 share stake
Zymeworks (NYSE: ZYME) maintained 1,311,085 share stake

* Since the original filing these positions have been updated further.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

13Fs, Hedge Funds